Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

NCT02260661 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Malignancies
Breast Cancer - ER+, HER2 -
Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation

Interventions

DRUG: AZD8835
DRUG: AZD8835
DRUG: AZD8835 in combination with fulvestrant
DRUG: AZD8835 in combination with fulvestrant

Sponsor

AstraZeneca